Welcome to our dedicated page for Pharma-Bio Serv news (Ticker: PBSV), a resource for investors and traders seeking the latest updates and insights on Pharma-Bio Serv stock.
Pharma-Bio Serv reports recurring updates as an OTCQB-traded consulting firm providing regulatory affairs, quality, compliance, project management and technology-transfer support to pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries. Company announcements primarily cover quarterly and annual operating results, revenue and net income trends, service-portfolio adjustments, cost-structure discipline, client and project activity, and special cash dividends approved by the board.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Pharma-Bio Serv, Inc. (OTCQB:PBSV) reported revenue of approximately $4.2 million for the quarter ending January 31, 2023, marking a decrease of $0.8 million year-over-year. However, net income rose to $0.4 million, an increase of $0.1 million compared to the previous year. The CEO, Mr. Sanchez, emphasized the strategic focus on more profitable markets, resulting in improved gross profit percentages. The company operates in markets including Puerto Rico, the US, Europe, and Latin America, providing regulatory compliance consulting services across various industries.
Pharma-Bio Serv (OTCQB:PBSV) has announced a Special Dividend of $0.075 per share, payable on or about April 14, 2023. This dividend is for shareholders of record as of the close of business on March 29, 2023. The company offers consulting services in regulatory compliance to various industries, including pharmaceuticals and biotechnology, mainly in Puerto Rico, the United States, Europe, and Latin America. The announcement reflects the company's commitment to returning value to its shareholders.
Pharma-Bio Serv (OTCQB:PBSV), a consulting firm in regulatory compliance, announced its partnership with ACP Capital Markets LLC for investment banking and M&A advisory services. This collaboration is aimed at strategically growing the company through potential acquisitions and enhancing shareholder value. CEO Victor Sanchez expressed optimism about working with ACP, highlighting their M&A expertise. Pharma-Bio Serv's services span across the pharmaceutical and biotechnology sectors, serving markets in Puerto Rico, the U.S., Europe, and Latin America. The company emphasizes regulatory compliance consulting, supported by a skilled global team.
Pharma-Bio Serv, Inc. (OTCQB:PBSV) reported fiscal year 2022 revenues of approximately $19.4 million, a decrease of $0.7 million compared to the previous year. However, net income improved to approximately $1.0 million, reflecting a $3.0 million increase year-over-year, influenced by a prior year's $5.2 million account receivable provision and $2.0 million PPP loan forgiveness. CEO Mr. Sanchez highlighted growth in the continental U.S. and European markets as a foundation for future expansion and strategic acquisitions aimed at maximizing shareholder value.
Pharma-Bio Serv, Inc. (OTCQB:PBSV) reported revenues of approximately $4.8 million for the three months and $14.8 million for the nine months ended July 31, 2022. This marks a slight decline of $0.2 million for the quarterly revenue compared to last year while showing an increase of $0.2 million year-to-date. Net income for both periods decreased by about $2.0 million due to prior year loan forgiveness. The company also continued its stock repurchase program, purchasing over 81,000 shares. CEO Mr. Sanchez highlighted growth in US and European consulting markets as a significant opportunity for expansion.
Pharma-Bio Serv (OTCQB:PBSV) reported revenue of approximately $5.0 million and $10.0 million for the three and six months ended April 30, 2022, marking increases of $0.1 million and $0.5 million respectively compared to the prior year. Net income remained stable at approximately $0.2 million and $0.5 million for the same periods. CEO Mr. Sanchez expressed satisfaction with the company’s consistent performance amidst economic uncertainties, emphasizing a strategy focused on expanding service offerings to existing clients while exploring new growth opportunities.